The U.S. Food and Drug Administration has granted accelerated approval to Bayer's HYRNUO (sevabertinib) for the first-line treatment of adult ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

FDA

U.S. FDA Grants Accelerated Approval to Bayer’s HYRNUO® (sevabertinib) as a First-Line Targeted Therapy for Patients with HER2-Mutated Non-Small Cell Lung CancerSeptember 9, 2026 10:21 PM